MMRC Horizon Two: A Phase II Randomized Adaptive Platform Trial Integrating Novel Therapies in High Risk Newly Diagnosed Multiple Myeloma

Full Title

MMRC Horizon Two: A Phase II Randomized Adaptive Platform Trial Integrating Novel Therapies in High Risk Newly Diagnosed Multiple Myeloma (WCG IRB)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description

Who Can Join

For more information or to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-3712.